New York City-based Pfizer earned approval from the Food and Drug Administration for its topical drug Eucrisa, reports Reuters.
Eucrisa, known under the generic name crisaborole, is intended to treat mild to moderate cases of eczema.
Pfizer gained rights to the drug through its $5.2 billion acquisition of Anacor Pharmaceuticals in the first half of 2016. The drugmaker predicts potential annual peak sales of Eucrisa to reach about $2 billion.
The drug will cost $580 for a two ounce tube and be available by the end of January, according to Pfizer.
More articles on supply chain:
Eli Lilly offers insulin discount after years of price hikes
7 supply chain lessons from auto and retail industries
FDA approves tissue repair system for knee cartilage injuries: 4 things to know